UK markets closed

Editas Medicine, Inc. (0IFK.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
7.79+0.79 (+11.31%)
At close: 07:07PM BST
Full screen
Previous close7.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range7.51 - 8.55
52-week range6.49 - 14.12
Avg. volume2,719
Market cap3.817M
Beta (5Y monthly)1.79
PE ratio (TTM)N/A
EPS (TTM)-2.73
Earnings date31 Oct 2023 - 06 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    Why Editas Medicine Stock Is Soaring Today

    What happened Shares of Editas Medicine (NASDAQ: EDIT) were soaring 11.2% higher as of 10:41 a.m. ET on Friday after vaulting as much as 24% earlier in the day. The big gain came after Stifel analyst Dae Gon Ha upgraded the stock from hold to buy.

  • Motley Fool

    1 Gene Editing Stock to Buy Now, and 1 to Sell

    In our modern age, the power of gene editing is undeniable. One stock with an encouraging outlook is gene-editing biotech Caribou Biosciences (NASDAQ: CRBU). The Berkeley, California-based company has two cancer programs in phase 1 trials: one for relapsed or refractory B-cell non-Hodgkin lymphoma, and another to treat relapsed or refractory multiple myeloma.

  • Zacks

    Ultragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock?

    Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.